Multiple Sclerosis, often referred to as MS, is a disease which causes the body’s immune system to attack and destroy the protective covering of nerves. Once this covering, called myelin, is degraded, the nerve fibers begin to disintegrate which often leads to severe physical debilitation.
One of the most effective treatment therapies for MS is the use of immunosuppressant drugs. Glatiramer acetate (Copaxone) is one such drug currently in clinical use. Cannabidiol, one of the main non-psychoactive compounds found in the cannabis plant (often referred to as CBD), has previously demonstrated immunosuppressant properties which encouraged a new study examining the effectiveness of CBD as a treatment therapy option for MS patients.
Researchers at the Hadassah Medical School at The Hebrew University of Jerusalem compared the effectiveness of CBD and the cannabis indica subspecies known as Avidekel with Copaxone. Avidekel is known for its extremely high CBD content, paired with very low amounts of THC. The data from their research demonstrated that the Avidekel extract and CBD were as effective as Copaxone at alleviating MS symptoms in mice and acted as an immunosuppressant.
While more research and clinical trials are required, preliminary data suggests that CBD could be a viable treatment therapy option for multiple sclerosis. Unlike Copaxone, CBD does not have to be injected, which could result in fewer doctor visits and is a readily available all-natural product. To buy cbd rich hemp oil and organic cbd hemp oil, visit our website at www.BuyNectarCBD.com.
To read more about the aforementioned study, please follow this link.